Effects of denosumab and alendronate on skeletal microarchitecture
Ego Seeman(The University of Melbourne), José Zanchetta(Universidad del Salvador), Angela M. Cheung(Westat (United States)), Steven K. Boyd(Alberta Bone and Joint Health Institute), Ann E. Kearns(Mayo Clinic), David A. Hanley(The University of Sydney), Elizabeth Shane(Columbia University Irving Medical Center), Deborah E. Sellmeyer(University of California, San Francisco), Thierry Thomas(Lyon 1 Université), Pierre D. Delmas(Inserm), César E. Bogado(Universidad del Salvador), Michelle Fan(National Cancer Centre Japan), Cesar Libanati(Amgen (United States)), S. Majumdar(University of California, San Francisco), Stéphanie Boutroy(Université Claude Bernard Lyon 1)
Cited by 1
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Functional Disability 5 Years after Acute Respiratory Distress Syndrome
|New England Journal of Medicine|2011|2.8k
Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women
|New England Journal of Medicine|1997|1.6k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k